MCID: DBT006
MIFTS: 47

Diabetic Macular Edema malady

Categories: Cardiovascular diseases, Eye diseases

Aliases & Classifications for Diabetic Macular Edema

Aliases & Descriptions for Diabetic Macular Edema:

Name: Diabetic Macular Edema 12 52 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:9191
ICD9CM 35 362.07
SNOMED-CT 64 312912001
UMLS 69 C0730285

Summaries for Diabetic Macular Edema

MalaCards based summary : Diabetic Macular Edema is related to retinitis and endotheliitis. An important gene associated with Diabetic Macular Edema is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are PEDF Induced Signaling and TGF-Beta Pathway. The drugs Dexamethasone and Pioglitazone have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and retina, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Diabetic Macular Edema

Diseases related to Diabetic Macular Edema via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 84)
id Related Disease Score Top Affiliating Genes
1 retinitis 10.6
2 endotheliitis 10.4
3 craniosynostosis, type 1 10.2 IL6 VEGFA
4 degenerative disc disease 10.2 IL6 VEGFA
5 vitamin a embryopathy 10.2 EPO IL6
6 cataract 10.2
7 cutaneous candidiasis 10.2 CCL2 ICAM1
8 angular blepharoconjunctivitis 10.2 IL6 SERPINF1 VEGFA
9 cardiac tuberculosis 10.2 IL6 VEGFA
10 ectodermal dysplasia bartalos type 10.2 IL6 SERPINF1 VEGFA
11 atherosclerosis 10.2 EPO IL6
12 aortic aneurysm 10.1 VEGFA VEGFC
13 vernal conjunctivitis 10.1 ICAM1 SERPINF1 VEGFA
14 intracranial cysts 10.1 NOS3 VEGFA
15 oculocutaneous albinism 10.1 SST VEGFA
16 adult infiltrating astrocytic neoplasm 10.1 CCL2 SERPINF1 VEGFA
17 albinism, oculocutaneous, type ib 10.1 EPO SERPINF1 VEGFA
18 cryptosporidiosis 10.1 CCL2 IL6 VEGFA
19 schwannoma of ureter 10.1 CCL2 IL6
20 vitreous detachment 10.1
21 benign familial neonatal epilepsy 10.1 SERPINF1 VEGFA VEGFC
22 malignant neoplasm of acoustic nerve 10.1 CCL2 ICAM1 VEGFA
23 neuroaxonal dystrophy 10.1 CCL2 ICAM1 IL6
24 acute panmyelosis with myelofibrosis 10.1 EPO IL6
25 amelogenesis imperfecta 10.1 CCL2 ICAM1 IL6
26 interval angle-closure glaucoma 10.1 CCL2 NOS3
27 sclerosing adenosis of breast 10.0 CCL2 ICAM1 IL6
28 neonatal jaundice 10.0 CCL2 ICAM1 IL6
29 immune system disease 10.0 CCL2 IL6 VEGFA
30 pigmentation disease 10.0 CCL2 ICAM1 IL6
31 bare lymphocyte syndrome, type i 10.0 CCL2 ICAM1 IL6
32 acute chest syndrome 10.0 CCL2 ICAM1 IL6
33 calcinosis 10.0 CCL2 EPO IL6
34 retinal vein occlusion 10.0
35 retinal detachment 10.0
36 myelophthisic anemia 10.0 CCL2 ICAM1 IL6
37 scar contracture 10.0 CCL2 IL6 SERPINF1 VEGFA
38 limb ischemia 10.0 ICAM1 IL6 NOS3
39 diabetic encephalopathy 10.0 ICAM1 IL6 NOS3
40 bipolar i disorder 10.0 FGF2 IL6 VEGFA
41 capillary hemangioma 10.0 NOS3 SST VEGFA
42 subdural empyema 10.0 FGF2 SERPINF1 VEGFA
43 latent syphilis 10.0 ICAM1 IL6
44 fiedler's myocarditis 10.0 NOS3 SST VEGFA
45 urinary bladder posterior wall cancer 10.0 FGF2 IL6 VEGFA
46 choroiditis 9.9
47 ischemia 9.9
48 substance-induced psychosis 9.9 CCL2 IL6 VEGFA
49 anal paget's disease 9.9 FGF2 IL6
50 multilocular clear cell renal cell carcinoma 9.9 ICAM1 IL6 PRKCB SERPINF1 VEGFA

Graphical network of the top 20 diseases related to Diabetic Macular Edema:



Diseases related to Diabetic Macular Edema

Symptoms & Phenotypes for Diabetic Macular Edema

MGI Mouse Phenotypes related to Diabetic Macular Edema:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.11 EPO FGF2 ICAM1 IL6 NOS3 PRKCB
2 homeostasis/metabolism MP:0005376 10.02 EPO FGF2 ICAM1 IL6 NOS3 PRKCB
3 immune system MP:0005387 10.02 NOS3 PRKCB SERPINF1 SST VEGFA VEGFC
4 hematopoietic system MP:0005397 10.01 SERPINF1 VEGFA EPO FGF2 ICAM1 IL6
5 digestive/alimentary MP:0005381 9.91 ICAM1 IL6 NOS3 SERPINF1 SST VEGFA
6 nervous system MP:0003631 9.76 FGF2 SERPINF1 SST VEGFA ICAM1 IL6
7 muscle MP:0005369 9.73 EPO FGF2 ICAM1 IL6 NOS3 VEGFA
8 skeleton MP:0005390 9.5 EPO FGF2 IL6 NOS3 SERPINF1 SST
9 vision/eye MP:0005391 9.1 FGF2 ICAM1 IL6 NOS3 SERPINF1 VEGFA

Drugs & Therapeutics for Diabetic Macular Edema

Drugs for Diabetic Macular Edema (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 267)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-02-2 5743
2
Pioglitazone Approved, Investigational Phase 4,Phase 2 111025-46-8 4829
3
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
4
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 124-94-7 31307
5
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
6
Nepafenac Approved Phase 4,Phase 3,Phase 2 78281-72-8 151075
7
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
8
Temazepam Approved Phase 4,Phase 3 846-50-4 5391
9
Povidone-iodine Approved Phase 4 25655-41-8
10
Zinc Approved Phase 4 7440-66-6 32051 23994
11
Betamethasone Approved, Vet_approved Phase 4,Phase 2,Phase 3 378-44-9 9782
12
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
13
Ketorolac Approved Phase 4,Phase 2 74103-06-3, 66635-83-4 3826
14
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
15
Menthol Approved Phase 4 2216-51-5 16666
16
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Early Phase 1 67-73-2 6215
17
Insulin Glargine Approved Phase 4 160337-95-1
18
Glimepiride Approved Phase 4 93479-97-1 3476
19
Verteporfin Approved, Investigational Phase 4 129497-78-5
20
Empagliflozin Approved Phase 4 864070-44-0
21
Benzocaine Approved Phase 4,Phase 1,Phase 2 1994-09-7, 94-09-7 2337
22
Linagliptin Approved Phase 4 668270-12-0 10096344
23 tannic acid Approved, Nutraceutical Phase 4,Phase 1,Phase 2
24
Bromfenac Approved July 1997 Phase 4,Phase 3,Phase 1 91714-94-2 60726
25 triamcinolone acetonide Phase 4,Phase 3,Phase 2,Phase 1
26 insulin Phase 4,Phase 3,Phase 1
27 Dexamethasone acetate Phase 4,Phase 2,Phase 3,Phase 1 1177-87-3
28 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
29 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
30
protease inhibitors Phase 4,Phase 2,Phase 3
31 Mitogens Phase 4,Phase 3,Phase 2,Phase 1
32 GABA Agents Phase 4,Phase 3
33 GABA Modulators Phase 4,Phase 3
34 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1
35 Neurotransmitter Agents Phase 4,Phase 3,Phase 1,Phase 2
36 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
37 Glycoside Hydrolase Inhibitors Phase 4
38 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3
39 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
40 Dermatologic Agents Phase 4,Phase 3,Phase 1,Phase 2
41 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
42 Ophthalmic Solutions Phase 4,Phase 2,Phase 3,Phase 1
43 Dexamethasone 21-phosphate Phase 4,Phase 2,Phase 3,Phase 1
44 Tranquilizing Agents Phase 4,Phase 3,Phase 2
45 Triamcinolone diacetate Phase 4,Phase 3,Phase 2,Phase 1
46 Triamcinolone hexacetonide Phase 4,Phase 3,Phase 2,Phase 1
47 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
48 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
49 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
50 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 465)
id Name Status NCT ID Phase
1 Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema Unknown status NCT02055911 Phase 4
2 Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4
3 POSTERIOR SUB-TENON'S Avastin Unknown status NCT00567372 Phase 4
4 The Endurance 1 Trial Unknown status NCT02297204 Phase 4
5 Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macular Edema Unknown status NCT02399657 Phase 4
6 Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation Unknown status NCT00804206 Phase 4
7 Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4
8 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
9 Changes in Macular Thickness After Patterns Scan Laser Unknown status NCT00563628 Phase 4
10 Intravitreal Macugen for Ischaemic Diabetic Macular Oedema Completed NCT01175070 Phase 4
11 Intraocular Anti-VEGF Compared With Intraocular Triamcinolone in Patients With Diabetic Macular Edema Completed NCT00682539 Phase 4
12 A Pilot Study on the Effect and Safety of Iluvien® in Chronic Diabetic Macular Edema Patients Completed NCT02359526 Phase 4
13 Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema Completed NCT02646670 Phase 4
14 Topical Nepafenac as Supplement for Diabetic Macular Edema Completed NCT02443012 Phase 4
15 Efficacy Study of Triamcinolone and Bevacizumab Intravitreal for Treatment of Diabetic Macular Edema Completed NCT00737971 Phase 4
16 Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema Completed NCT02036424 Phase 4
17 Ozurdex as Adjunct to Avastin Compared to Avastin Alone in Treatment of Patients With Diabetic Macular Edema Completed NCT01309451 Phase 4
18 Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema. Completed NCT00758628 Phase 4
19 Unilateral Bevacizumab for Bilateral Diabetic Macular Edema Completed NCT00496405 Phase 4
20 Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study) Completed NCT01613716 Phase 4
21 Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema Completed NCT01546402 Phase 4
22 Ranibizumab "Treat and Extend" in Diabetic Macular Edma Completed NCT01297569 Phase 4
23 Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment Completed NCT01257815 Phase 4
24 Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study Completed NCT01486238 Phase 4
25 Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema. Completed NCT02140411 Phase 4
26 Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial Completed NCT02299336 Phase 4
27 A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticost Completed NCT02472366 Phase 4
28 Lucentis (Ranibizumab) in Diabetic Macular Oedema: a Treatment Evaluation Completed NCT01223612 Phase 4
29 Morphological and Functional Retinal Changes Following Retinal Photocoagulation Completed NCT00682240 Phase 4
30 A Clinical Study in Current Medical Practice of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema Completed NCT01315275 Phase 4
31 TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema Completed NCT01870440 Phase 4
32 Avastin for Post-Photocoagulation Macular Edema Completed NCT00801866 Phase 4
33 Effect of the Adjunctive IVB Before PRP Completed NCT01504724 Phase 4
34 Effect of Preoperative Topical Ketorolac on Aqueous Cytokine Levels and Macular Thickness in Cataract Surgery Patients Completed NCT02646072 Phase 4
35 Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients Completed NCT00174824 Phase 4
36 20- Versus 23- Gauge System for Pars Plana Vitrectomy Completed NCT00411970 Phase 4
37 Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Diabetic Macular Edema Recruiting NCT02441907 Phase 4
38 Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema Recruiting NCT02471651 Phase 4
39 Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular Edema Recruiting NCT02924987 Phase 4
40 Aflibercept anD navigateD vErsus coNvensional Laser in Diabetic macUlar edeMa Recruiting NCT02554747 Phase 4
41 Influence of Diabetes Control on Treatment of Diabetic Macular Edema With Ranibizumab Recruiting NCT02665689 Phase 4
42 Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema Recruiting NCT02684084 Phase 4
43 Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis Recruiting NCT03097068 Phase 4
44 Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab Recruiting NCT02559180 Phase 4
45 Treat-and-extend Regimen of Aflibercept in Diabetic Macular Edema (VIBIM Study) Recruiting NCT02788877 Phase 4
46 Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema Recruiting NCT02985242 Phase 4
47 Laser Therapy Combined With Intravitreal Aflibercept vs Intravitreal Aflibercept Monotherapy (LADAMO) Recruiting NCT02432547 Phase 4
48 Continuation of Previous Study to Gather More Data on Effect of Macugen on the Corneal Endothelium Recruiting NCT01573572 Phase 4
49 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion Recruiting NCT01827722 Phase 4
50 Cohort Study of the Clinical Course of Macular Diseases in Kagawa Recruiting NCT02321267 Phase 4

Search NIH Clinical Center for Diabetic Macular Edema

Genetic Tests for Diabetic Macular Edema

Anatomical Context for Diabetic Macular Edema

MalaCards organs/tissues related to Diabetic Macular Edema:

39
Eye, Endothelial, Retina, Testes

Publications for Diabetic Macular Edema

Articles related to Diabetic Macular Edema:

(show top 50) (show all 643)
id Title Authors Year
1
Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy. ( 28061854 )
2017
2
Re: Wells etA al.: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial (Ophthalmology 2016;123:1351-1359). ( 27993278 )
2017
3
INTEGRITY OF OUTER RETINAL LAYERS AFTER RESOLUTION OF CENTRAL INVOLVED DIABETIC MACULAR EDEMA. ( 28092342 )
2017
4
Evidence-Based Treatment of Diabetic Macular Edema. ( 28060586 )
2017
5
Efficacy of 0.2a88I1g/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy. ( 28085139 )
2017
6
A Revised Approach for the Detection of Sight-Threatening Diabetic Macular Edema. ( 27930756 )
2017
7
Dexamethasone Implants in Patients with Naive Diabetic Macular Edema. ( 27173167 )
2016
8
Anti-vascular endothelial growth factor treatment in diabetic macular edema. ( 27621645 )
2016
9
Vitrectomy for center-involved diabetic macular edema. ( 27175056 )
2016
10
Intravitreal Injection of Ozurdex(Ar) Implant in Patients with Persistent Diabetic Macular Edema, with Six-Month Follow-Up. ( 27147895 )
2016
11
Diabetic Retinopathy and Diabetic Macular Edema. ( 26501152 )
2016
12
Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness. ( 27631479 )
2016
13
Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. ( 27601878 )
2016
14
Dexamethasone Implant in Chronic Diabetic Macular Edema Resistant to Intravitreal Ranibizumab Treatment. ( 27926909 )
2016
15
Treatments for Diabetic Macular Edema: Past, Present, and Future. ( 27631474 )
2016
16
Intravitreal Diclofenac plus Bevacizumab versus Bevacizumab alone in treatment-naive diabetic macular edema: a randomized double-blind clinical trial. ( 27624173 )
2016
17
STRUCTURAL-FUNCTIONAL CORRELATION IN PATIENTS WITH DIABETIC MACULAR EDEMA. ( 27575411 )
2016
18
Intravitreal injection of methotrexate in persistent diabetic macular edema: a 6-month follow-up study. ( 27145784 )
2016
19
Comorbidity and health care visit burden in working-age commercially insured patients with diabetic macular edema. ( 27994438 )
2016
20
Machine learning based detection of age-related macular degeneration (AMD) and diabetic macular edema (DME) from optical coherence tomography (OCT) images. ( 28018716 )
2016
21
Evaluating Effects of Switching Anti-Vascular Endothelial Growth Factor Drugs for Age-Related Macular Degeneration and Diabetic Macular Edema. ( 28006042 )
2016
22
Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema. ( 27621587 )
2016
23
Longitudinal Study of Sustained-Release Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema. ( 27169611 )
2016
24
Intravitreal Aflibercept Injection in Eyes With Substantial Vision Loss After Laser Photocoagulation for Diabetic Macular Edema: Subanalysis of the VISTA and VIVID Randomized Clinical Trials. ( 28006063 )
2016
25
Influence of the epiretinal membrane on ranibizumab therapy outcomes in patients with diabetic macular edema. ( 28076563 )
2016
26
Restoration of foveal photoreceptors after intravitreal ranibizumab injections for diabetic macular edema. ( 27966644 )
2016
27
Pathophysiology and pharmacological targets of VEGF in diabetic macular edema. ( 26607863 )
2016
28
Reduction of Diabetic Macular Edema in the Untreated Fellow Eye Following Intravitreal Injection of Aflibercept. ( 27183553 )
2016
29
CORRELATION BETWEEN CYSTOID SPACES IN CHRONIC DIABETIC MACULAR EDEMA AND CAPILLARY NONPERFUSION DETECTED BY OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY. ( 28005668 )
2016
30
Early and Long-term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data. ( 27644589 )
2016
31
Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. ( 27651226 )
2016
32
Clinical effects and safety of treating diabetic macular edema with intravitreal injection of ranibizumab combined with retinal photocoagulation. ( 27103811 )
2016
33
PACAP and VIP Inhibit HIF-1I+-Mediated VEGF Expression in a Model of Diabetic Macular Edema. ( 27661459 )
2016
34
Adjunct Intravitreous Triamcinolone Acetonide in the Treatment of Diabetic Macular Edema with Anti-VEGF Agents. ( 27980863 )
2016
35
Elevated Intraocular Pressure After Intravitreal Steroid Injection in Diabetic Macular Edema: Monitoring and Management. ( 27164896 )
2016
36
Quantitative Assessment of Optic Nerve Changes in Patients With Diabetic Macular Edema Treated With Fluocinolone Acetonide Vitreous Implants. ( 27183545 )
2016
37
Diabetic Macular Edema. ( 27182271 )
2016
38
Multimodal retinal imaging of diabetic macular edema: toward new paradigms of pathophysiology. ( 27154296 )
2016
39
PARS PLANA VITRECTOMY FOR DIABETIC MACULAR EDEMA: A Systematic Review, Meta-Analysis, and Synthesis of Safety Literature. ( 27632713 )
2016
40
Author's reply to comments to: Long-term efficacy and safety of intravitreal dexamethasone implant for the treatment of diabetic macular edema. ( 27646338 )
2016
41
Spectral Domain Optical Coherence Tomography Features and Classification Systems for Diabetic Macular Edema: A Review. ( 27632028 )
2016
42
Pearl necklace sign in diabetic macular edema: Evaluation and significance. ( 27958206 )
2016
43
PROSPECTIVE RANDOMIZED SUBJECT-MASKED STUDY OF INTRAVITREAL BEVACIZUMAB MONOTHERAPY VERSUS DEXAMETHASONE IMPLANT MONOTHERAPY IN THE TREATMENT OF PERSISTENT DIABETIC MACULAR EDEMA. ( 27124881 )
2016
44
Predictors of Diabetic Macular Edema Treatment Frequency with Ranibizumab During the Open-Label Extension of the RIDE and RISE Trials. ( 27208982 )
2016
45
Real-world outcomes of ranibizumab treatment for diabetic macular edema in a United Kingdom National Health Service setting. ( 27637784 )
2016
46
Subfoveal choroidal thickness changes after intravitreal bevacizumab injection for neovascular age-related macular degeneration and diabetic macular edema. ( 27154721 )
2016
47
Bromfenac eyedrops in the treatment of diabetic macular edema: a pilot study. ( 28009414 )
2016
48
Further Scrutiny of Vision Outcomes When Aflibercept Is Used as Rescue Treatment for Eyes With Diabetic Macular Edema Treated With Laser. ( 28006049 )
2016
49
Comments to: Long-term efficacy and safety of intravitreal dexamethasone implant for the treatment of diabetic macular edema. ( 27646326 )
2016
50
Update on corticosteroids for diabetic macular edema. ( 27660409 )
2016

Variations for Diabetic Macular Edema

Expression for Diabetic Macular Edema

Search GEO for disease gene expression data for Diabetic Macular Edema.

Pathways for Diabetic Macular Edema

Pathways related to Diabetic Macular Edema according to GeneCards Suite gene sharing:

(show all 42)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.46 CCL2 EPO IL6 NOS3 PRKCB SERPINF1
2
Show member pathways
13.4 CCL2 EPO FGF2 ICAM1 IL6 VEGFA
3
Show member pathways
13.27 CCL2 FGF2 IL6 NOS3 PRKCB VEGFC
4
Show member pathways
13.15 FGF2 IL6 NOS3 PRKCB VEGFA VEGFC
5
Show member pathways
12.92 CCL2 FGF2 IL6 PRKCB VEGFC
6
Show member pathways
12.67 CCL2 ICAM1 IL6 PRKCB
7
Show member pathways
12.62 FGF2 PRKCB VEGFA VEGFC
8
Show member pathways
12.58 FGF2 IL6 PRKCB VEGFC
9 12.57 FGF2 IL6 PRKCB VEGFA VEGFC
10
Show member pathways
12.56 CCL2 ICAM1 NOS3 PRKCB VEGFA
11
Show member pathways
12.47 CCL2 FGF2 IL6 NOS3
12 12.27 EPO FGF2 IL6 NOS3 VEGFA VEGFC
13
Show member pathways
12.26 NOS3 PRKCB VEGFA VEGFC
14
Show member pathways
12.22 CCL2 ICAM1 NOS3 PRKCB VEGFA
15 12.07 IL6 SST VEGFA
16
Show member pathways
12.05 FGF2 NOS3 PRKCB VEGFA VEGFC
17 11.98 CCL2 ICAM1 NOS3 VEGFA
18 11.97 FGF2 IL6 VEGFA
19 11.91 CCL2 ICAM1 IL6
20
Show member pathways
11.86 IL6 NOS3 PRKCB
21 11.83 CCL2 ICAM1 IL6 VEGFC
22
Show member pathways
11.77 NOS3 VEGFA VEGFC
23 11.73 CCL2 ICAM1 IL6 VEGFA
24 11.7 CCL2 FGF2 NOS3 VEGFC
25 11.61 CCL2 FGF2 ICAM1 IL6 VEGFA
26 11.59 CCL2 FGF2 IL6
27
Show member pathways
11.58 ICAM1 IL6 VEGFA
28 11.46 CCL2 ICAM1 IL6
29 11.46 CCL2 ICAM1 IL6
30 11.4 EPO NOS3 VEGFA VEGFC
31 11.35 EPO IL6 NOS3 PRKCB VEGFA
32 11.3 EPO FGF2 IL6 VEGFA
33 11.28 ICAM1 IL6 PRKCB
34 11.26 CCL2 IL6 NOS3
35 11.16 CCL2 ICAM1 IL6 NOS3 PRKCB VEGFA
36 11.1 FGF2 VEGFA
37 11.08 CCL2 ICAM1
38 11.07 FGF2 NOS3 VEGFA
39 10.95 CCL2 VEGFA
40 10.87 CCL2 ICAM1
41
Show member pathways
10.86 VEGFA VEGFC
42 10.58 VEGFA VEGFC

GO Terms for Diabetic Macular Edema

Cellular components related to Diabetic Macular Edema according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 CCL2 EPO FGF2 IL6 SERPINF1 SST
2 extracellular space GO:0005615 9.28 CCL2 EPO FGF2 ICAM1 IL6 SERPINF1

Biological processes related to Diabetic Macular Edema according to GeneCards Suite gene sharing:

(show all 44)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.98 IL6 NOS3 SST VEGFC
2 positive regulation of cell proliferation GO:0008284 9.98 EPO FGF2 IL6 VEGFA VEGFC
3 response to drug GO:0042493 9.89 CCL2 ICAM1 IL6 SST VEGFC
4 response to lipopolysaccharide GO:0032496 9.87 CCL2 EPO ICAM1 IL6
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.85 ICAM1 IL6 PRKCB
6 cellular response to lipopolysaccharide GO:0071222 9.85 CCL2 ICAM1 IL6
7 animal organ morphogenesis GO:0009887 9.84 CCL2 FGF2 VEGFC
8 aging GO:0007568 9.84 CCL2 EPO IL6 SERPINF1
9 cellular response to tumor necrosis factor GO:0071356 9.83 CCL2 ICAM1 IL6
10 angiogenesis GO:0001525 9.83 CCL2 FGF2 NOS3 VEGFA VEGFC
11 positive regulation of neuron projection development GO:0010976 9.81 EPO IL6 SERPINF1
12 regulation of cell shape GO:0008360 9.81 CCL2 ICAM1 IL6 VEGFA
13 cellular response to interleukin-1 GO:0071347 9.8 CCL2 ICAM1 IL6
14 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.79 CCL2 VEGFA VEGFC
15 positive regulation of epithelial cell proliferation GO:0050679 9.78 IL6 VEGFA VEGFC
16 cellular response to glucose stimulus GO:0071333 9.77 CCL2 ICAM1 SERPINF1
17 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.77 CCL2 EPO FGF2 ICAM1 IL6
18 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.76 ICAM1 IL6 VEGFA VEGFC
19 negative regulation of neuron death GO:1901215 9.75 EPO IL6 SERPINF1
20 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.73 EPO IL6 VEGFA
21 positive regulation of cell division GO:0051781 9.72 FGF2 VEGFA VEGFC
22 positive regulation of endothelial cell proliferation GO:0001938 9.71 CCL2 FGF2 VEGFA VEGFC
23 positive chemotaxis GO:0050918 9.7 FGF2 VEGFA VEGFC
24 negative regulation of blood pressure GO:0045776 9.69 NOS3 VEGFC
25 response to electrical stimulus GO:0051602 9.69 EPO IL6
26 positive regulation of protein autophosphorylation GO:0031954 9.69 VEGFA VEGFC
27 positive regulation of neuroblast proliferation GO:0002052 9.68 VEGFA VEGFC
28 cellular response to interleukin-6 GO:0071354 9.68 CCL2 ICAM1
29 cell migration involved in sprouting angiogenesis GO:0002042 9.67 FGF2 VEGFA
30 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.67 PRKCB VEGFA
31 induction of positive chemotaxis GO:0050930 9.66 VEGFA VEGFC
32 positive regulation of leukocyte migration GO:0002687 9.65 CCL2 VEGFA
33 negative regulation of calcium ion transport GO:0051926 9.65 ICAM1 NOS3
34 positive regulation of blood vessel endothelial cell migration GO:0043536 9.65 FGF2 VEGFA VEGFC
35 response to acidic pH GO:0010447 9.64 SERPINF1 SST
36 cellular response to nutrient levels GO:0031669 9.64 ICAM1 IL6
37 positive regulation of cellular extravasation GO:0002693 9.62 CCL2 ICAM1
38 response to heat GO:0009408 9.62 CCL2 IL6 NOS3 SST
39 positive regulation of mast cell chemotaxis GO:0060754 9.61 VEGFA VEGFC
40 regulation of vascular endothelial growth factor production GO:0010574 9.6 CCL2 IL6
41 response to amino acid GO:0043200 9.56 CCL2 ICAM1 IL6 SST
42 cellular response to dexamethasone stimulus GO:0071549 9.46 CCL2 ICAM1 IL6 SERPINF1
43 positive regulation of angiogenesis GO:0045766 9.35 FGF2 NOS3 PRKCB VEGFA VEGFC
44 response to hypoxia GO:0001666 9.1 CCL2 EPO ICAM1 PRKCB VEGFA VEGFC

Molecular functions related to Diabetic Macular Edema according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.46 CCL2 FGF2 IL6 VEGFA
2 heparin binding GO:0008201 9.43 CCL2 FGF2 VEGFA
3 growth factor activity GO:0008083 9.26 FGF2 IL6 VEGFA VEGFC
4 chemoattractant activity GO:0042056 8.8 FGF2 VEGFA VEGFC

Sources for Diabetic Macular Edema

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....